Stockscreener 앱 받기
13.89
0.22%
0.03
전일 마감가:
$13.86
열려 있는:
$13.86
하루 거래량:
1.92M
Relative Volume:
0.38
시가총액:
$996.61M
수익:
-
순이익/손실:
$-192.96M
주가수익비율:
-4.2091
EPS:
-3.3
순현금흐름:
$-167.04M
1주 성능:
+0.58%
1개월 성능:
+69.18%
6개월 성능:
+343.77%
1년 성능:
+634.92%
1일 변동 폭
$13.85
$13.90
1주일 범위
$13.80
$13.90
52주 변동 폭
$0.783
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
명칭
Ventyx Biosciences Inc
전화
(760) 407-6511
주소
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
VTYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
13.89 | 994.46M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-03-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-03-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-11-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-11-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Wells Fargo | Overweight |
| 2022-12-19 | 개시 | Goldman | Buy |
| 2022-11-17 | 개시 | Morgan Stanley | Overweight |
| 2022-09-07 | 개시 | Stifel | Buy |
| 2022-09-01 | 개시 | H.C. Wainwright | Buy |
| 2022-05-09 | 개시 | Credit Suisse | Outperform |
| 2022-03-31 | 개시 | Canaccord Genuity | Buy |
| 2022-02-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-15 | 개시 | Jefferies | Buy |
| 2021-11-15 | 개시 | Piper Sandler | Overweight |
모두보기
Ventyx Biosciences Inc 주식(VTYX)의 최신 뉴스
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion, Strategizing Beyond Weight Management Drugs - Intellectia AI
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? - The Globe and Mail
Halper Sadeh Investigates ON24, Ventyx, and Sun Country for Potential Violations - Intellectia AI
Halper Sadeh LLC Encourages ONTF, VTYX, SNCY Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
EV Market: Is Ventyx Biosciences Inc. stock forming a triangle patternJuly 2025 Trends & Accurate Intraday Trading Signals - baoquankhu1.vn
Analyst Calls: Will Ventyx Biosciences Inc stock hit new highs in YEARQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Citizens Financial Group Inc. RI Takes Position in Ventyx Biosciences, Inc. $VTYX - MarketBeat
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation - FinancialContent
Aug Sectors: What are Ventyx Biosciences Incs earnings expectationsWall Street Watch & Free Long-Term Investment Growth Plans - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc.VTYX - Your Wyoming Link
Daily Breeze - FinancialContent
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - Finviz
Halper Sadeh LLC Encourages VTYX, SNCY, EKSO Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Halper Sadeh LLC Encourages VTYX, FONR, SNCY, FFIC Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Upcoming Events - FinancialContent
HC Wainwright Has Negative Estimate for VTYX FY2029 Earnings - MarketBeat
Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences - Insider Monkey
Ventyx Biosciences (NASDAQ:VTYX) Rating Lowered to "Hold" at UBS Group - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Downgraded by Wells Fargo & Company to "Hold" - MarketBeat
Key facts: Eli Lilly to acquire Ventyx for $1.2B; Mounjaro pricing in India; AI partnership with Revvity - TradingView — Track All Markets
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences - FinancialContent
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition - Dealbreaker
Ventyx Biosciences (NASDAQ:VTYX) Rating Lowered to "Hold" at Lifesci Capital - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Downgraded to Hold Rating by Clear Str - MarketBeat
Ventyx Biosciences (VTYX) Downgraded by Wells Fargo to Equal-Wei - GuruFocus
Will Ventyx Biosciences Inc. stock split attract more investorsStock Surge & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Ventyx Biosciences to be Sold to Eli Lilly for $14 per Share - Intellectia AI
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Invest - GuruFocus
Lilly To Buy Ventyx Biosciences For $1.2 Billion To Expand Oral Inflammation Pipeline - Pulse 2.0
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc.VTYX - Morningstar
Ventyx Biosciences Faces Allegations of Misleading Information, Stock Drops 15.35% - Intellectia AI
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Prime Publishers, Inc.
Eli Lilly nears deal for Ventyx Biosciences at $14/shareWSJ - MSN
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly - Wilson Sonsini
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition By Investing.com - Investing.com Nigeria
Ventyx’s NLRP3 inhibitors best in class? Lilly offers $1.2B - BioWorld MedTech
Is Ventyx Biosciences Inc. stock a defensive play in 2025Forecast Cut & Weekly Stock Breakout Alerts - ulpravda.ru
FDA Limits Oversight of Fitness Wearables as Eli Lilly Acquires Ventyx Biosciences in $1 Billion Deal - geneonline.com
2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition - Law360
Lilly Snags Ventyx For $1.2 Billion; Who Else Benefits? - Investor's Business Daily
Ventyx Biosciences (NASDAQ:VTYX) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Eli Lilly Scoops Up Ventyx Biosciences in $1.2 Billion Acquisition - NAVLIN DAILY
Lilly to acquire Ventyx Biosciences stock for $14 per share By Investing.com - Investing.com South Africa
Lilly’s Ventyx Buyout Will Swell Interest In NLRP3 inhibitors - Citeline News & Insights
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX) - marketscreener.com
Lilly buys Ventyx in $1.2bn deal to tackle chronic inflammation - BioXconomy
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences - PharmExec.com
Eli Lilly (LLY) Buys Ventyx Biosciences in $1.2 Billion Deal - TipRanks
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal - Asianet Newsable
Ventyx Biosciences (NASDAQ:VTYX) Given Equal Weight Rating at Wells Fargo & Company - MarketBeat
Ventyx Biosciences Inc (VTYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ventyx Biosciences Inc 주식 (VTYX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Dec 18 '25 |
Sale |
7.72 |
47,345 |
365,461 |
2,372,863 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 17 '25 |
Option Exercise |
0.00 |
34,930 |
0 |
502,156 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 18 '25 |
Sale |
7.72 |
12,675 |
97,840 |
489,481 |
4.73%
0.92%
자본화:
|
볼륨(24시간):